You would have to be a clueless imbecile or a lying short, and possibly both to say ONXX has cash flow or cash reserve problems. Even more hilarious is someone talking about revenues from 2 years ago, let alone to 6 months ago as if they were relevant. ONXX is flush with cash and revenues are dramatically increasing after the Kyprolis approval, and the rising usage of Stivarga.
It's ironic that after the major selloff of the last two sessions, today early stage stocks such as ONXX, MDVN, and PCYC are doing much better than the more established biotechs such as GILD and CELG, which have only managed weak bounces today. Quite simply, I think, these are stocks which, if you sell them as the market deteriorates, you will quickly buy them back. It's actually dangerous not to be in them.
I had osulinn on "ignore", but I went back and read his posts for the amusement factor. You flatter him by assuming that he has the courage or capital to go short. Whenever anyone predicts huge price declines for one of these stocks, you can be sure that he has only gambled a few bucks on some cheap puts. I'm thinking that those July75's at a buck apiece would be about his speed.